GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (STU:BPXA) » Definitions » Inventories, Finished Goods

Bellicum Pharmaceuticals (STU:BPXA) Inventories, Finished Goods : €0.00 Mil (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Inventories, Finished Goods?


Bellicum Pharmaceuticals Inventories, Finished Goods Historical Data

The historical data trend for Bellicum Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Inventories, Finished Goods Chart

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bellicum Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Bellicum Pharmaceuticals (STU:BPXA) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (STU:BPXA) Headlines

No Headlines